Phase 2b randomized, double-blind, placebo-controlled study of Nitric-oxide in Pulmonary-hypertension patients associated with Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2018
Price : $35 *
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- 07 Nov 2018 According to the Bellerophon Therapeutics media release, the company expects to initiate this trial in 2019.
- 17 May 2018 According to the Bellerophon Therapeutics media release, company in conjunction with its steering committee finalized the design of this trial and agreement with the FDA has been reached on the design of this trial.
- 17 May 2018 New trial record